<sup>64</sup>Cu-NOTA-bevacizumab immunoreactivity.
- Albert J. Chang (389411)
- Rebecca Sohn (389412)
- Zhi Hong Lu (389413)
- Jeffrey M. Arbeit (159402)
- Suzanne E. Lapi (389414)
Publication date
March 2013
DOIAbstract
<p>Increased binding of <sup>64</sup>Cu-NOTA-bevacizumab was observed with increasing concentration of VEGF. The inhibitable binding blockade using 20 µg unlabeled bevacizumab highlights the tracer specificity. All assays were conducted in triplicate. Bars shown are +/− standard deviation.</p
Add to ORKG